To evaluate the effectiveness of the INTEGRAL-Risk model in classifying patients at risk for lung cancer within one year, specifically comparing it to the US Preventive Services Task Force criteria and the PLCOm2012 model.
Key Findings:
The INTEGRAL-Risk model achieved an area under the curve of 0.88 for predicting lung cancer within 1 year, outperforming the PLCOm2012 model (0.79).
At a specificity threshold matching the 2021 USPSTF criteria, the INTEGRAL-Risk model captured 85% of lung cancer cases within 1 year.
The model demonstrated improved discrimination among various racial and ethnic groups, particularly among Asian, non-Hispanic Black, and non-Hispanic White participants.
Performance metrics declined over longer prediction horizons, with areas under the curve of 0.84 at 2 years and 0.81 at 3 years.
Interpretation:
The INTEGRAL-Risk model shows promise in refining eligibility for lung cancer screening, particularly in identifying high-risk individuals.
Limitations:
The study did not assess lung cancer mortality, false-positive results, screening risks, cost-effectiveness, or implementation feasibility.
The model underpredicted risk among Asian and non-Hispanic Black participants, indicating a need for recalibration.
The researchers could not assess whether the INTEGRAL-Risk model differentiated lung cancers with different driver sequence variants due to unavailable data.
Conclusion:
The INTEGRAL-Risk model may enhance the selection of individuals for lung cancer screening, but further adequately powered prospective studies are required before broader implementation.
Research highlights expanding diagnostic capabilities but persistent gaps in antiviral therapy and vaccine coverage for pediatric enterovirus infections.
